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Abstract
Respiratory viruses are a cause of upper respiratory tract infections (URTI), but can be asso-
ciated with severe lower respiratory tract infections (LRTI) in immunocompromised patients.
The objective of this study was to investigate the genetic variability of influenza virus, parain-
fluenza virus and respiratory syncytial virus (RSV) and the duration of viral shedding in
hematological patients. Nasopharyngeal swabs from hematological patients were screened
for influenza, parainfluenza and RSV on admission as well as on development of respiratory
symptoms. Consecutive swabs were collected until viral clearance. Out of 672 tested
patients, a total of 111 patients (17%) were infected with one of the investigated viral agents:
40 with influenza, 13 with parainfluenza and 64 with RSV; six patients had influenza/RSV or
parainfluenza/RSV co-infections. The majority of infected patients (n = 75/111) underwent
stem cell transplantation (42 autologous, 48 allogeneic, 15 autologous and allogeneic). LRTI
was observed in 48 patients, of whom 15 patients developed severe LRTI, and 13 patients
with respiratory tract infection died. Phylogenetic analysis revealed a variety of influenza A
(H1N1)pdm09, A(H3N2), influenza B, parainfluenza 3 and RSV A, B viruses. RSV A was
detected in 54 patients, RSV B in ten patients. The newly emerging RSV A genotype ON1
predominated in the study cohort and was found in 48 (75%) of 64 RSV-infected patients.
Furthermore, two distinct clusters were detected for RSV A genotype ON1, identical RSV G
gene sequences in these patients are consistent with nosocomial transmission. Long-term
viral shedding for more than 30 days was significantly associated with prior allogeneic trans-
plantation (p = 0.01) and was most pronounced in patients with RSV infection (n = 16) with a
median duration of viral shedding for 80 days (range 35–334 days). Long-term shedding of
respiratory viruses might be a catalyzer of nosocomial transmission and must be considered
for efficient infection control in immunocompromised patients.
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Introduction
In winter 2012/2013, the number of viral respiratory tract infections in Germany was the high-
est observed during the past decade. Infections with respiratory viruses are a common cause of
usually mild respiratory illness in all age groups. Immunosuppressed adults and elderly persons
with underlying chronic conditions, however, are at increased risk for a severe course of disease
[1–4]. In hematopoietic stem cell recipients, respiratory viruses cause higher rates of lower
respiratory tract disease and are associated with a higher mortality rate [5–9]. For patients with
hematological disorders presenting with respiratory symptoms, a screening for influenza virus,
parainfluenza virus and respiratory syncytial virus (RSV) is recommended [10, 11].
Although a vaccine against seasonal and pandemic influenza is available, vaccines against
parainfluenza and RSV are still under development [6, 12]. However, the effect of vaccination
in immunosuppressed patients is limited. As the major pathogen causing severe lower respira-
tory tract disease in immunocompromised adults, RSV is of high priority for vaccine develop-
ment. RSV infections only partially induce protective immunity, and repeated infections occur
in childhood and throughout life [13]. Strain variation in respiratory viruses is thought to con-
tribute to their ability to cause frequent reinfections [14]. The attachment protein of RSV is
able to accommodate changes with the emergence of new variants. Sequencing of hypervariable
gene regions has been widely used to further subdivide parainfluenza and RSV into genotypes
and facilitate differentiation between virus isolates. Influenza viruses are highly variable and
characterized by a continuous genetic and antigenic drift. Accumulation of mutations espe-
cially in the antigenic sites of the hemagglutinin is the cause of the emergence of new drift vari-
ants and the co-circulation of different groups and lineages.
Viral shedding studies provide fundamental information about the natural course of respi-
ratory virus infections, related clinical illness and the implementation of effective prevention
strategies. Influenza is generally a self-limiting infection with systemic and respiratory symp-
toms, usually resolving within 3 to 6 days in most patients. Viral clearance in the respiratory
tract usually occurs after 3 to 5 days [15]. However, in immunocompromised patients respira-
tory viruses tend to persist longer due to a constrained immune response and therefore also
spread more easily into the lower respiratory tract. Prolonged influenza and RSV viral shedding
has been previously described in immunocompromised patients [16–18] and similar results
have been observed for rhinovirus and coronavirus [19]. However, there is only limited infor-
mation regarding the molecular epidemiology of respiratory viruses in immunocompromised
adults combined with the prevalence, duration and clinical impact of viral shedding.
In our study, we retrospectively investigated patients with respiratory tract infection in the
hematology and transplant unit of the University Hospital Heidelberg between December 2012
and May 2013. We performed molecular characterization of influenza virus, parainfluenza
virus and RSV investigating their genetic diversity and patterns of co-circulating subtypes and
genotypes. Furthermore, we assessed the prevalence, duration and clinical impact of prolonged
viral shedding in immunocompromised adults.
Materials and Methods
Patients and infection control
The Heidelberg University Hospital is a tertiary referral center. The department of hematology
comprises four inpatient wards for adult patients—two wards for normal and high-dose che-
motherapy, one intermediate care unit and one transplant unit—as well as several outpatient
clinics and a day hospital where chemotherapy on an outpatient basis is administered. Most of
the patients treated suffer from malignant lymphoma, multiple myeloma, and acute leukemia.
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Each year about 200–250 autologous and 100–120 allogeneic transplantations are performed.
The majority of allogeneic transplant patients receive peripheral blood stem cells after a
reduced conditioning regimen.
As part of the standard operation procedures and in order to inform for infection control
measures, from autumn to spring all hematological patients are tested on development of respi-
ratory symptoms for infection with influenza virus, parainfluenza virus and RSV (standard
screening); during the summer months only patients with very severe or not otherwise explica-
ble symptoms are tested due to the lower prevalence of respiratory virus infections in that sea-
son. With significantly increasing numbers of respiratory infections, standard screening was
escalated in February 2013 and subsequently all patients were screened for infection with influ-
enza virus, parainfluenza virus and RSV on admission to one of the wards regardless of respira-
tory symptoms as well as tested again once respiratory symptoms developed (intensified
screening). Additional screening for other community acquired viruses such as rhino-, adeno-
or coronavirus was not performed. All patients with proven viral infection were retested until
clearance of virus. Several patients were lost to follow-up regarding their viral shedding. Fur-
thermore, symptomatic patients were isolated while awaiting the laboratory result. Infected
patients were isolated in single rooms or isolated in cohorts.
The samples were processed within two hours and afterwards kept frozen at -20°C. Analysis
was performed with nasopharyngeal samples via reverse transcription polymerase chain reac-
tion (RT-PCR). A case of respiratory tract infection was based on a laboratory-confirmed infec-
tion with influenza virus, parainfluenza virus or RSV presenting with or without respiratory
symptoms. URTI was defined as presence of respiratory symptoms (e.g. coughing, sneezing)
without signs of lower respiratory tract disease, LRTI was defined as presence of respiratory
symptoms plus radiographic (chest X-ray or chest CT scan) signs of lower respiratory tract dis-
ease, severe LRTI was defined as LRTI plus requirement of treatment on the intensive care unit
or death. Nosocomial infections were defined as virus detection on day seven or later after
admission to the ward, the remainders were defined as community-acquired infection. How-
ever, some of the community-acquired cases had been previously treated at the day hospital.
Patient records and information were anonymized and de-identified prior to analysis. Ethical
approval was obtained from the Ethical Committee of the University of Heidelberg.
Sample collection
For the purpose of this study, nasopharyngeal swabs of all inpatients and outpatients who were
screened for the respiratory viruses influenza, parainfluenza and RSV during the winter season
2012/2013 were retrospectively analysed. For some of the LRTI patients, additional bronchoal-
veolar lavage (BAL) samples were available. Readily available medical records were retrospec-
tively reviewed from all patients to obtain basic characteristics, clinical and laboratory data.
Reverse transcription polymerase chain reaction (RT-PCR)
RNA was extracted from respiratory specimens using the QIAamp1 viral RNAmini kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s protocol. Reverse transcription, amplifi-
cation and detection of viral RNA was performed with the RealStar1 Influenza, Parainfluenza
and RSV real-time RT-PCR kits (altona Diagnostics, Hamburg, Germany) on a LightCycler1
480 instrument II (Roche, Mannheim, Germany) according to the manufacturer's instructions.
These assays distinguished influenza A, B, H1N1, RSV A, and RSV B. The RealStar Parainflu-
enza RT-PCR kit cannot differentiate between parainfluenza virus types 1 and 3 and between
types 2 and 4. Therefore, the FTD Respiratory pathogens 21 kit (Fast Track Diagnostics, Luxem-
bourg) was used for typing of samples positive for parainfluenza virus RNA.
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Sequencing and phylogenetic analysis
Extracted RNA was reverse transcribed using random hexamer primers. Subsequently, influ-
enza virus hemagglutinin (HA) gene, parainfluenza virus 3 F (fusion) gene and the second vari-
able region of the RSV G (attachment) gene were amplified from cDNA. Primer sequences for
amplification of influenza virus HA genes are available on request. For parainfluenza virus 3,
primers PIV3-4885s (5’- AAAGAGGTCAACACCAACAACT-3’) and PIV3-5285a (5’-
TGTATTGCTTGATCTGTTGGTC- 3’) were used. RSV primers were described previously
[20]. Resulting PCR products were sequenced completely in both directions using Big Dye ter-
minator chemistry version 1.1 and the instrument Prism 3130xl (Applied Biosystems, Darm-
stadt, Germany). Overlapping sequences were assembled using the SEQMAN II software of the
Lasergene package (DNAstar, Madison, USA). Multiple alignments from influenza virus, para-
influenza virus and RSV nucleotide sequences were carried out with the MEGA software ver-
sion 5.05. A phylogenetic tree was constructed in MEGA using the maximum-likelihood
method and the Tamura-Nei algorithm for influenza virus phylogenetic analysis MEGA ver-
sion 5.2, the neighbor joining method and the Kimura 2-parameter were used [21, 22]. Repre-
sentative reference sequences for influenza, parainfluenza and RSV genotypes were obtained
from GenBank (http://www.ncbi.nlm.nih.gov), GISAID (global initiative on sharing all influ-
enza data, www.gisaid.org) and sequences representing influenza viruses circulating in Ger-
many were provided by the National Reference Centre for Influenza and included in the
phylogenetic analysis. The statistical significance of the tree topology was assessed by boot-
strapping with 1000 replicates. Nucleotide sequences retrieved in this study were deposited in
GenBank under accession numbers [KJ938237-KJ938299].
Viral shedding
Follow-up of shedding of RSV-infected patients was conducted on wards as well as in the out-
patient facility. Analysis of the duration of shedding was performed among all cases with sam-
ples available from at least two consecutive weeks. Total duration of viral shedding for a given
infection was calculated from the first positive to the final positive sample, allowing no more
than four weeks or one negative sample between any two consecutive positive samples. A previ-
ously infected patient was considered to have cleared the infection when he/she was asymp-
tomatic and had two nasopharyngeal samples taken a week apart that tested negative
Statistical analysis
We used Stata version 11 (Stata Corp., College Station, TX, USA) for all statistical analyses.
Fisher’s exact test was applied for univariate analyses, logistic regression models were used for
multivariate analyses.
Results
Epidemiology and laboratory results
In November and December 2012, a few sporadic cases of patients with respiratory virus infec-
tion were detected by PCR. Escalated screening of all patients to be admitted was performed
starting in week 8 to week 16 in 2013, when a significant increase of infected patients was
observed. The total number of patients admitted for any reason to one of the four hematologic
wards was 421 (148 female, 273 male) from November 2012 to January 2013, and 341 (123
female, 218 male) from February to April 2013. Between November 2012 and April 2013, a
total of 672 patients with hematological disorders were tested for presence of influenza virus,
parainfluenza virus or RSV, 111 patients were found to be infected, 40 patients were with
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influenza virus, 13 patients with parainfluenza virus and 64 patients with RSV, six patients had
co-infections (influenza virus/RSV: n = 5; parainfluenza virus/RSV: n = 1). According to the
case definition, 30 of 40 (75%) influenza infections, 11 of 13 (84%) parainfluenza infections
and 36 of 64 (56%) RSV infections were community-acquired. The epidemiological curve of
respiratory infections is shown in Fig 1.
Infection control measures
Standard infection control measures included isolation of patients who were tested positive for
one of the respiratory viruses until two consecutive negative swabs were obtained. Cohort isola-
tion of patients infected with the same virus was possible. Contact patients were isolated until a
negative swab was obtained at the end of the estimated incubation period. Masks were to be
worn in all patient rooms on the transplant unit, on the intermediate care ward as well as when
in contact with infected patients. Rigorous hand hygiene was implemented.
During the period of intensified screening, infection control measures were intensified to
isolation of all newly admitted patients as well as all patients who developed respiratory symp-
toms until a negative swab was obtained. The number of visitors allowed was reduced to two
visitors per person and children under the age of twelve were no longer admitted to the wards.
Masks were obligatory on all the wards.
Neither visitors nor medical or nursing staff were screened for presence of respiratory
viruses. However, visitors with respiratory symptoms were not admissible to the wards and
medical or nursing staff experiencing respiratory symptoms was discouraged from having
direct patient contact.
Clinical outcome
The mean age of the all infected patients was 57.1 years (range 19–84 years) with a male:female
ratio of 1.9:1. The distribution of the underlying hematological disorders was similar to the
overall patient population at the department of hematology. The majority of infected patients
(n = 75/111) underwent stem cell transplantation (42 autologous, 48 allogeneic, 15 autologous
and allogeneic); 13 patients were infected pre-engraftment, 62 post-engraftment. All but three
patients were considered immunocompromised for one or more of the following reasons:
Fig 1. Cases of influenza virus, parainfluenza virus and RSV infections in the hematology unit during
the winter of 2012/2013 by week of laboratory confirmation.
doi:10.1371/journal.pone.0148258.g001
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uncontrolled hematological malignancy, chemotherapy,< 3 months after transplantation,
prior steroid treatment, systemic immunosuppression, reduced CD4+ T-cell count, hypogam-
maglobulinemia. Details on clinical characteristics of infected patients are presented in Table 1.
Sixty four patients had URTI, 47 patients showed signs of LRTI, and 15 patients developed
severe LRTI as defined by ICU treatment or fatal outcome. Thirteen infected patients with
pneumonia died, despite ICU admission and supportive ventilation. Five of the fatal cases were
infected with influenza virus, one with parainfluenza virus and seven with RSV. Oral tamiflu or
ribavirin was given as treatment to 60 patients, immunoglobuline preparations to 13 patients,
palivizumab was not administered. There were no significant differences in regard to demo-
graphic and clinical characteristics between influenza, parainfluenza and RSV infected patients.
Furthermore, we could not identify any association between a specific virus group and a more
severe course of illness. Co-infections were detected in 30 patients. A total of 44 different co-
detected pathogens could be identified (bacterial 27, viral 11, fungal 6), e.g. Pseudomonas aeru-
ginosa bacteremia, cytomegalovirus reactivation, and Aspergillus fumigatus pneumonia. Risk
factor assessment amongst all infected patients showed by univariate analysis for the endpoint
LRTI uncontrolled hematological disease (OR 4.39 [95% CI 1.70;11.84], p = 0.001), presence of
co-infections (OR 5.82 [95% CI 2.07;17.82, p = 0.0002), and prior steroid therapy (OR 3.32
[95% CI 1.14;11.13], p = 0.02) as significant risk factors; a trend was seen for severe leukopenia
(i.e. leukocytes<1/nl)>10 days (OR 3.22 [95% CI 0.88;13.34], p = 0.07). In regard of the end-
point severe LRTI only presence of co-infections (OR 4.89 [95% CI 1.31;19.39], p = 0.008) was
a significant risk factor; a trend was seen for uncontrolled hematological disease (OR 3.42 [95%
CI 0.93;13.28], p = 0.06). By multivariate analysis no significant influence factors could be
identified.
Phylogenetic analysis and genotype distribution pattern
For a subset of 15 influenza-infected patients, 10 parainfluenza-infected patients and all 64
RSV-infected patients, enough sample material was available for further phylogenetic analysis.
Table 1. Basic characteristics of patients with respiratory virus infections in the study cohort.
all n = 111a influenza n = 40 parainfluenza n = 13 RSV n = 64
median age (range) 57.1 (19–84) years 57.6 (21–84) years 60.6 (41–74) years 56.8 (19–73) years
ratio male:female 1.9:1 2.6:1 3.3:1 1.7:1
underlying disease
AML/MDS 27 12 2 15
ALL/LBL 11 4 0 7
NHL/HL 27 10 3 16
MM 35 10 6 21
other 11 4 2 5
transplant status
autologous 42 10 5 29
allogeneic 48 15 6 32
auto/allo 15 4 3 9
LRTI 48 15 5 28
fatal outcome 13 5 1 7
a 6 patients with coinfections (n = 5 influenza/RSV, n = 1 parainfluenza/RSV)
ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; HL: Hodgkin’s lymphoma; LBL: lymphoblastic lymphoma; LRTI: lower respiratory tract
infection; MM: multiple myeloma; MDS: myelodysplastic syndrome; NHL: non-Hodgkin lymphoma; RSV: respiratory syncytial virus
doi:10.1371/journal.pone.0148258.t001
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For influenza virus, five samples were determined as influenza A(H1N1)pdm09, six samples as
influenza A(H3N2) and four samples as influenza B viruses belonging to the Yamagata-lineage.
Phylogenetic analysis of the A(H1N1)pdm09 HA sequences revealed that the HA genes form
seven genetic groups, wherein the group 1 represents the reference strain A/California/7/2009.
During the 2012/13 season group 6 and 7 viruses co-circulated in Germany. Group 6 viruses
dominated comprising the genetic subgroups 6A, 6B and 6C. The here identified A(H1N1)
pdm09 viruses belonged to the subgroups 6A (n = 1), 6C (n = 2), and group 7 (n = 2) (data not
shown). Molecular analysis of the A(H3N2) viruses showed that two variants co-circulated in
Germany during the season 2012/13 corresponding to the genetic groups 3C and 5. Group 3C
viruses dominated comprising the genetic subgroups 3C.1, 3C.2 and 3C.3. The here detected A
(H3N2) viruses belonged to group 5 (n = 1), subgroup 3C.2 (n = 2) and 3C.3 (n = 4). Among
the identified 3C.3 viruses two HA sequences were identical (Fig 2A). Since the 2001/02 season,
influenza B viruses of the Victoria- and Yamagata-lineage co-circulated with different seasonal
prevalence in the northern hemisphere. In the season 2012/13 the Yamagata-lineage was more
prevalent. These viruses are divided into group 2 and 3 viruses. All identified B/Yamagata-line-
age viruses analysed here cluster in group 2 and were characterised by identical HA sequences
(Fig 2B). Analyzed parainfluenza virus positive samples revealed type 2 (one sample), type 3 (8
samples) and type 4 (1 sample), no identical parainfluenza type 3 strains were found (Fig 3).
RSV group specific PCR determined 54 RSV A and 10 RSV B infected patients. Sequences
of the second hypervariable region of the G gene from these samples were successfully obtained
and aligned with representative RSV sequences. Phylogenetic trees of RSV A and B sequences
are shown in Fig 4A and 4B, respectively. The majority of RSV-A strains (n = 49, 90%) clus-
tered with strains that were previously assigned to the novel ON1 genotype with a 72 nucleo-
tide duplication, followed by strains clustering with genotype NA1 (Fig 3A). Two clusters were
identified within the genotype ON1 subgroup, cluster 1 with 15 patients harboring identical
RSV A ON1 strain G gene sequence and cluster 2 comprising 12 patients with another set of
identical G gene sequence (Fig 4A). Thus, 27 (50%) of 54 RSV A infected patients carried simi-
lar virus strains. In each of these clusters, the first patient, i.e. P25 in cluster 1 and P28 in cluster
2 had a community-acquired infection, while all subsequently following patients were nosoco-
mially infected. There were no significant differences in regard to severity and outcome of
infection between the two clusters with 41% vs 42% asymptomatic/URTI only, 47% vs 33%
non-severe LRTI, 12% vs 25% severe LRTI, and 12% vs 8% fatal outcome in cluster 1 and 2,
respectively. All RSV-B strains (n = 10) clustered with strains that were previously assigned to
the BA genotype with a 60 nucleotide duplication. BA strains could be further differentiated
into genotypes BA IX and X (Fig 3B).
Long-term virus detection
Patients with respiratory virus infections were followed-up in order to analyze viral detection.
Results for all infected patients with samples available from at least two consecutive weeks
(n = 69) are shown in Fig 5. Long-term virus detectionfor more than 30 days was detected in
20 (29%) infected patients, i.e. two influenza virus infections, two parainfluenza virus infec-
tions, and 16 RSV infections (Table 2). Comparing clinical characteristics between patients
with and without long-term virus detection revealed a significantly higher proportion of
patients following allogeneic transplantation in the long-term virus detection cohort (14/20 vs
34/91 patients, p = 0.01). In this context it is worth noticing that 5 out of 6 patients with
extreme long-term virus detection for 90 days had received an allogeneic transplant; the one
patient without allogeneic transplantation (P52) had received an autologous transplantation
but experienced graft-failure with long-term leukopenia. Regarding the morbidity associated
Long-Term Shedding of Respiratory Viruses
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Fig 2. Phylogenetic tree of influenza A(H3N2) (A) (nt78-nt1061) and B/Yamagata-lineage (B)
(nt100-nt571) virus sequences of the HA gene was constructed with MEGA version 5.2 using the
neighbor joiningmethod. Patient numbers are indicated, reference sequences for infuenza virus selected
from GISAID are indicated by their accession numbers. Additionally, HA sequences from german national
influenza sentinel are presented. The federal states are abbreviated as follows: Bayern (BAY), Baden-
Württemberg (BWB), Berlin (BLN), Brandenburg (BBG), Bremen (BRE), Hamburg (HAM), Hesse (HES),
Long-Term Shedding of Respiratory Viruses
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with viral infection there was no significant difference in the rate of LRTI development between
patients with and without long-term virus detection (11/20 vs 36/91, p = 0.22).
Six of 64 RSV-infected patients were infected for more than twelve weeks, all patients car-
ried RSV A genotype ON1, and belonged to either ON1 cluster 1 or cluster 2. An extensively
prolonged viral shedding was noted in this group of patients. One patient died while still being
infected with RSV A ON1, one RSV A ON1 infected patient was lost to follow-up. However, 18
of 20 (90%) patients with prolonged infection cleared viral infection as demonstrated by nega-
tive follow-up samples (Table 2). Long-term RSV-infected patients presented with a median
duration of viral shedding for 80 days, range 35–334 days (Table 2). Interestingly, 12 (75%) of
16 long-term RSV shedding patients were infected with identical RSV G gene sequences found
in phylogenetic genotype ON1 clusters 1 and 2. Patient P48, diagnosed with multiple myeloma,
had received autologous and allogeneic transplantation and was persistently infected for 334
days, followed by clearance of the infection.
Discussion
This surveillance study of influenza virus, parainfluenza virus and RSV infections in a large
cohort of patients with hematological malignancies provides insight into the molecular epide-
miology and circulation patterns of subtypes and genotypes of respiratory viruses in immuno-
compromised adults combined with the prevalence, duration and clinical impact of prolonged
viral shedding. Phylogenetic analysis revealed a variety of influenza A(H1N1)pdm09, A
(H3N2) and influenza B/Yamagata-lineage, parainfluenza 3 and RSV A, B viruses; whereof
about half of the patients (n = 54/111; 48.6%) were infected with RSV subtype A. Furthermore,
we describe the predominance of the newly described RSV genotype ON1 strain in RSV-
infected patients. Identification of two distinct clusters of RSV strains is consistent with
Mecklenburg-Western Pomerania (MVP), Lower Saxony (NSA), North Rhine-Westphalia (NRW), Rhineland-
Palatinate (RPF), Saarland (SAL), Saxony (SAS), Saxony-Anhalt (SAT), Schleswig-Holstein (SHO),
Thuringia (THR). Bootstrap values greater than 70 are displayed on branch nodes.
doi:10.1371/journal.pone.0148258.g002
Fig 3. Phylogenetic tree of parainfluenza virus sequences from the fusion gene was constructed with
MEGA version 5.05 using the maximum likelihoodmethod. Patient numbers are indicated, reference
sequences for parainfluenza virus type 3 selected from GenBank are indicated by their accession numbers.
Bar indicates 0.1 nucleotide substitutions per site. Bootstrap values greater than 60 are displayed on branch
nodes. Patient numbers of long-term virus shedding patients are indicated in bold.
doi:10.1371/journal.pone.0148258.g003
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Fig 4. Phylogenetic trees of RSV A (A) and RSV B (B) virus sequences from the second hypervariable
region of the attachment protein G gene were constructed with MEGA version 5.05 using the
maximum likelihoodmethod. Patient numbers are indicated, reference sequences for RSV A and RSV B
selected from GenBank are indicated by their accession numbers. Bar indicates 0.1 nucleotide substitutions
per site. Bootstrap values greater than 60 are displayed on branch nodes. Long-term RSV shedding patients
are marked with a black dot.
doi:10.1371/journal.pone.0148258.g004
Fig 5. Duration of influenza virus, parainfluenza virus and RSV shedding periods.
doi:10.1371/journal.pone.0148258.g005
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nosocomial spread being responsible for a significant proportion of observed infections. A
unique aspect of this analysis was the repeatedly performed screening of viral respiratory infec-
tions identifying 18% of patients as long-term infected with RSV with a median shedding dura-
tion of 80 days. The high prevalence of long-term shedding of respiratory viruses in
immunocompromised patients might increase the risk of nosocomial spread of infections and
should be taken into account when devising infection control measures.
In adult patients with hematological disorders and stem cell recipients, respiratory viruses
are an important cause of life-threatening pneumonia, and are associated with substantial mor-
bidity and mortality. A broader screening for respiratory pathogens in hematopoietic stem cell
transplant (HSCT) recipients has been recommended by several expert groups [10, 11]. Nearly
half of our parainfluenza infected patients developed LRTI, which is in accordance with a
report of Nichols et al. [23]. Nine of the fatal cases underwent blood stem cell transplantation,
three were autologous and six were allogeneic. Although respiratory viruses might cause fatal
pneumonia, the contribution of these agents to the fatal outcome is difficult to assess. Recently,
characteristic findings in chest CT scan at the beginning of RSV pneumonia with nodules and
tree-in-bud sign often combined with bronchial wall thickening have been described as patho-
gnomonic [24]. Systematic analysis of risk factors in this special cohort of patients revealed
hypogammaglobulinemia to be a significant risk factor for RSV-associated morbidity and mor-
tality, whereas treatment with oral ribavirin might provide a protective effect [18]. Progression
Table 2. Long-term viral sheddingmore than 30 days.
patient sex age underlying disease transplant status URTI/LRTI infection virus type shedding duration clearance
P31 m 66 CLL allogeneic URTI influenza H3N2 48 d yes
P32 m 34 ALL - URTI influenza H1N1 41 d yes
P33 m 55 MM auto/allo LRTI RSV A ON1 35 d yes
P48 m 52 MM auto/allo LRTI RSV A ON1 cluster 1 334 d yes
P51 m 69 MDS allogeneic LRTI RSV A ON1 cluster 1 111 d yes
P52 m 55 DLBCL autologous LRTI RSV A ON1 cluster 2 156 d noa
P55 m 66 MM autologous URTI RSV A ON1 cluster 1 40 d yes
P56 m 34 AML allogeneic LRTI RSV A ON1 cluster 2 90 d yes
P57 m 53 MM auto/allo LRTI RSV A ON1 cluster 1 39 d yes
P59 f 66 MM auto/allo URTI RSV A ON1 cluster 1 43 d yes
P61 m 54 MM autologous URTI RSV A ON1 cluster 1 57 d nob
P68 m 56 AML - LRTI RSV A ON1 cluster 2 33 d yes
P79 f 38 ALL allogeneic URTI RSV A ON1 cluster 1 91 d yes
P82 f 63 MM auto/allo LRTI RSV A ON1 cluster 1 38 d yes
P88 m 62 AML allogeneic URTI parainfluenza 3 30 d yes
P95 m 51 pancr. cancer allogeneic LRTI RSV A ON1 cluster 1 91 d yes
P102 m 49 ALL allogeneic URTI RSV A ON1 35 d yes
P103 f 55 TNHL - LRTI RSV B BA IX 40 d yes
P105 f 49 MM auto/allo LRTI parainfluenza 3 36 d yes
P107 f 71 Burkitt auto/allo URTI RSV A ON1 57 d yes
a died while still shedding,
b lost to follow-up; m: male,
f: female, ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; CLL: chronic lymphatic leukemia; DLBCL: diffuse large B-cell lymphoma; LRTI:
lower respiratory tract infection; MM: multiple myeloma; MDS: myelodysplastic syndrome; RSV: respiratory syncytial virus; TNHL: T-cell non-Hodgkin
lymphoma; URTI: upper respiratory tract infection
doi:10.1371/journal.pone.0148258.t002
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of RSV infection from URTI to LRTI is associated with an increased risk of death in these
patients, resulting in a 7%-70% case fatality rate among patients with hematological disorders
[2, 25, 26]. In a study of Milano et al. [19, the morbidity and mortality were relatively low in
HSCT patients infected with either rhinovirus or coronavirus, asymptomatic detections were
common.
Molecular characterization of respiratory viruses has the potential to aid in the identification
of infection chains. In our study cohort, nearly half of the patients with viral respiratory infec-
tions were infected with influenza virus or parainfluenza virus representing a broad spectrum
of different strains and types. Similar results for infections with influenza and parainfluenza
virus infections among patients with haematological disorders have been reported earlier [8].
Regarding the identified influenza infections in the immunocompromised patient group, A
(H1N1)pdm09, A(H3N2) and influenza B viruses have been detected. A similar prevalence of
co-circulating influenza virus types/subtypes during the season 2012/13 was reported by the
national influenza surveillance system in Germany [27]. The phylogenetic analysis revealed
that the prevalence of proven influenza A variants and influenza B-lineages in tested patient
specimens matched with those reported from the national and European influenza surveillance
systems [28]. Therefore, the same variants were identified in our population-based surveillance
and within our study cohort and no difference between variants causing mild and severe clini-
cal cases could be detected. Several nosocomial infections in immunocompromised patients
have been described for A(H1N1)pdm09 [29, 30]. In the present study, the identical influenza
A(H3N2) and influenza B/Yamagata-lineage HA sequences could give an indication of nosoco-
mial transmission. Immunocompromised patients were characterized by longer viral shedding
during the course of influenza virus infection [30]. The longer times of viral shedding in those
patients might favour nosocomial infection chains. Several lineages of RSV within groups A
and B co-circulate simultaneously in the population and their relative proportions may differ
between epidemics, although group A viruses tend to predominate. Sequencing of the variable
regions of the G protein gene has been widely used to further subdivide the two subtypes into
genotypes and facilitated differentiation between RSV isolates. In 1998, Peret al. established a
classification of different genotypes based on the analysis of the variability of RSV G gene [20].
To date, 11 RSV-A genotypes, GA1-GA5 [31], GA6-GA7 [32], SAA1 [33], NA1-NA2 [34], and
ON1 [35], and 23 RSV-B genotypes, GB1-GB4 [31], SAB1-SAB3 [33], SAB4 [36],
URU1-URU2 [37], BAI–BAVI [38], BAVII–BAX [39], BAXI [40], BAXII [41], and THB [42]
have been established based on phylogenetic analysis of nucleotide sequences. Studies on RSV
strains show an accumulation of amino acid changes over the years, suggesting antigenic drift-
based immunity-mediated selection [32, 33]. The European pattern in seasonal activity of RSV
usually alternates in a regular biennial rhythm; an early season with strong RSV activity is fol-
lowed by a weaker late season [43]. A seasonality of viral acute respiratory infections influenced
by meteorological conditions has been described previously [5]. The vast majority of identified
RSV-A strains clustered with strains that were just recently assigned to the novel ON1 geno-
type with a 72 nucleotide duplication, first described by Eshaghi et al. [34] in Ontario, Canada,
in 2010. In Germany, circulation of this genotype was reported for the first time in winter
2011/2012 [35]. In line with another study in Europe, this study reports ON1 as the predomi-
nant genotype during the RSV epidemic season 2012/2013, suggesting a rapid spread of this
emerging RSV strain [36]. Two distinct phylogenetic clusters were identified within the geno-
type ON1 subgroup and fifty percent of RSV A infected patients carried similar virus strains.
All RSV-B strains clustered with strains that were previously assigned to the BA genotype with
a 60 nucleotide duplication [37]. RSV lineages similar to the strain in our patients were simul-
taneously circulating in Germany in the same winter in children [3]. In line with the gradual
spread of the BA genotype, making it the dominant circulating RSV-B genotype today, might
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result in a shift to the predominant genotype ON1. There is an increasing number of reports
from across the world describing this novel genotype and the following seasons will show its
full impact on the evolution of RSV-A [39]. The nucleotide duplication of the ON1 genotype
seems to be beneficial for the virus, the novel strain shows an improved ability to evade previ-
ously induced immunity in the population suggesting an immune-escape strategy. Several RSV
outbreaks among hospitalized hematology patients have been reported in the past [17, 40]. In
one study involving post bone marrow transplant patients, it was found that nosocomial infec-
tion with RSV occurred in almost half of all patients on the ward [8], nosocomial transmission
might be reduced by an enhanced infection control program. The presence of two distinct clus-
ters points to nosocomial transmission, detected one week or later after admission.
The mean incubation period of respiratory virus infections in immunocompetent patients is
stated as four days, but can vary between two to eight days [42]. However, persistence of viral
shedding has received little attention in immunocompromised patients. An important observa-
tion in this study was the prolonged viral shedding and hence the carrier status of the patients
affected. Long-term viral shedding for more than 30 days was detected in 18% of patients in
our patient cohort, mostly associated with RSV. Seventeen of 20 patients with prolonged viral
shedding were transplant patients, 13 patients with allogeneic transplants. This finding is in
line with a recent study from Heidelberg, where the majority of patients with respiratory viral
shedding for more than four weeks were allogeneic transplant recipients [22]. According to
Khanna et al. [43], duration of viral shedding is not associated with immunosuppression, RSV
subtype or treatment regimen. Since these patients shed for a long time, it seems prudent to
assume that these patients remain positive for the duration of their hospital stay. This finding
confirms previous reports of prolonged shedding among immunocompromised patients [17,
19]. Shedding in hematology patients was reported for 2–4 weeks [43–45]. However, this is the
first time that for RSV a median shedding duration as long as 12 weeks has been reported.
Recently, Milano et al. [19] reported prolonged viral shedding in hematopoietic stem cell trans-
plantation recipients. Median duration of viral shedding for rhinovirus and coronavirus was
five weeks and four weeks, respectively, and prolonged shedding of more than three months
was observed in some patients.
Nosocomial transmission seems to have been responsible for a significant proportion of
the infections observed in our cohort of immunocompromised patients. One might speculate
on a chain of infection consisting of a limited number of viral strains being introduced from
the community to the hospital, both by the patients themselves as may be by visitors and
staff, and spread then nosocomially, further facilitated by prolonged viral shedding in the
immunocompromised host. To avoid this self-reinforcing circle early detection and isolation
of infected patients as well as rigorous hygienic measures are of key importance. Infection
control measures should include systematic screening of patients taking into account the
incubation periods when testing contact patients, regular re-testing of positive patients to
assess prolonged viral shedding, as well as—if feasible—preemptive isolation of possibly
infected patients.
Influenza is preventable by vaccination, which is recommended for high-risk populations,
immunosuppressed patients and patients with chronic medical conditions [46]. Vaccines for
parainfluenza and RSV are not licensed yet, a newly developed vaccine against parainfluenza
virus was immunogenic and well-tolerated in seronegative young children [6]. The develop-
ment of a vaccine could prevent RSV-related pneumonia in adults [47] and induction of neu-
tralizing antibodies with an RSV vaccine may potentially reduce disease severity in adult
populations. New strategies such as RNAi therapeutics have been shown to exert potent antivi-
ral effects against influenza, parainfluenza and RSV in vitro and in vivo [48]. Molecular
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epidemiological studies of these viruses provide useful information for the development of
globally effective vaccines.
This study is subject to several limitations. The study population is a heterogeneous group
in regard to a variety of aspects: patients and samples were obtained based on a routine screen-
ing for respiratory viruses. Initially, patients were screened for respiratory viruses due to clini-
cally manifest respiratory symptoms, whereas later on screening was escalated to weekly
screening of all patients regardless of clinical symptoms. In addition, a mixed cohort of in-
patients and outpatients were included in this study. Regarding the treatment of viral infec-
tions, nearly all influenza-infected patients received oseltamivir, however therapies such as
immunoglobulin preparations or ribavirin were optional for RSV infected patients and were
given mainly at the discretion of the attending physician. Finally, both non-transplant and
transplant patients were included. According to the ECIL guidelines [10], the panel of the
tested viruses was restricted to influenza virus, parainfluenza virus and respiratory syncytial
virus. Other viruses, e.g. metapneumovirus is not recommended in the ECIL first line testing of
these patients and testing was not performed.
In conclusion, 17% of immunocompromised haematological patients who were screened
for presence of influenza virus, parainfluenza virus or RSV were tested positive for one of these
three respiratory viruses with RSV accounting for more than half of the detected infections the
newly emerged RSV A genotype ON1 predominated in the study cohort. The global spread
and progressive diversification of ON1 strains into several lineages resembles the evolution of
the RSV-B BA genotype. Further molecular investigations are needed to understand possible
immunological or biological causes of the improved viral fitness of genotypes containing a
duplicated region in the G gene. In line with the emergence of the BA genotype, it can be
hypothesized that genotype ON1 could spread in a similar way and several lineages might sub-
divide into further genotypes.
Distinct phylogenetic clusters of genotype RSV ON1 strains and identical HA sequences of
influenza viruses identified in these patients might also indicate nosocomial transmission. Pro-
longed virus shedding was observed especially in patients with RSV infection and following
allogeneic transplantation and might have facilitated nosocomial spreading. It poses a major
challenge for infection control management in hospital settings with immunocompromised
patients and should be taken into account when devising infection control measures.
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